LY-2940094

LY-2940094
Clinical data
Routes of
administration		 Oral

LY-2940094 is a potent and selective nociceptin receptor antagonist which is under investigation by Eli Lilly for the treatment of major depressive disorder and alcohol dependence.[1][2] It has demonstrated proof-of-concept clinical efficacy for depression.[3] As of 2015, it is in phase II clinical trials for both of the aforementioned indications.[1][2] Its chemical structure has yet to be published.[1]

See also

References

  1. 1 2 3 Dale, Elena; Bang-Andersen, Benny; Sánchez, Connie (2015). "Emerging mechanisms and treatments for depression beyond SSRIs and SNRIs" (PDF). Biochemical Pharmacology 95 (2): 81–97. doi:10.1016/j.bcp.2015.03.011. ISSN 0006-2952. PMID 25813654.
  2. 1 2 Yin, Xin; Guven, Nuri; Dietis, Nikolas (2015). "Opioids in Depression: Not Quite There Yet" (PDF). UK Journal of Pharmaceutical and Biosciences 3 (1): 12–17.
  3. ↑ Post A, Smart TS, Krikke-Workel J, Dawson GR, Harmer CJ, Browning M, Jackson K, Kakar R, Mohs R, Statnick M, Wafford K, McCarthy A, Barth V, Witkin JM (2015). "A Selective Nociceptin Receptor Antagonist to Treat Depression: Evidence from Preclinical and Clinical Studies". Neuropsychopharmacology. doi:10.1038/npp.2015.348. PMID 26585287.

External links


This article is issued from Wikipedia - version of the Saturday, April 02, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.